Progression‐free survival · platinum‐sensitive recurrent EOC
Summary of findings 1: PLD with chemotherapy probably leads to lower progression‐free survival (PFS) compared with alternative combination chemotherapy (moderate certainty).
1 finding from 1 review
Hand‐foot syndrome (grade ≥ 3) · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy probably leads to lower hand‐foot syndrome (grade ≥ 3) compared with PLD alone (moderate certainty).
1 finding from 1 review
Neurological (grade ≥ 3) · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy showed no clear difference in neurological (grade ≥ 3) compared with PLD alone (low certainty).
1 finding from 1 review
QoL · platinum‐sensitive recurrent EOC
1 finding from 1 review
Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC
Summary of findings 1: PLD with chemotherapy showed no clear difference in overall severe adverse events (grade ≥ 3) compared with alternative combination chemotherapy (moderate certainty).
1 finding from 1 review
Anaemia (grade ≥ 3) · platinum‐sensitive recurrent EOC
Summary of findings 1: PLD with chemotherapy probably leads to higher anaemia (grade ≥ 3) compared with alternative combination chemotherapy (moderate certainty).
1 finding from 1 review
Hand‐foot syndrome (grade ≥ 3) · platinum‐sensitive recurrent EOC
It is very uncertain whether summary of findings 1: PLD with chemotherapy changes hand‐foot syndrome (grade ≥ 3) compared with alternative combination chemotherapy (very low certainty).
1 finding from 1 review
Neurological (grade ≥ 3) · platinum‐sensitive recurrent EOC
It is very uncertain whether summary of findings 1: PLD with chemotherapy changes neurological (grade ≥ 3) compared with alternative combination chemotherapy (very low certainty).
1 finding from 1 review
Overall survival (OS) · recurrent platinum‐resistant EOC
Summary of findings 2: PLD alone showed no clear difference in overall survival (OS) compared with other conventional chemotherapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · recurrent platinum‐resistant EOC
It is very uncertain whether summary of findings 2: PLD alone changes progression‐free survival (PFS) compared with other conventional chemotherapy (very low certainty).
1 finding from 1 review
Intervention not reported
PFS¹ · women with newly diagnosed EOC (stage Ic to IV)
The intervention showed no clear difference in PFS¹ (high certainty).
1 finding from 1 review
Intervention not reported
OS² · women with newly diagnosed EOC (stage Ic to IV)
The intervention showed no clear difference in OS² (high certainty).
1 finding from 1 review
Intervention not reported
Anaemia (grade 3/4) · women with newly diagnosed EOC (stage Ic to IV)
The intervention leads to higher anaemia (grade 3/4) (high certainty).
1 finding from 1 review
Intervention not reported
Thrombocytopenia (grade 3/4) · women with newly diagnosed EOC (stage Ic to IV)
The intervention leads to higher thrombocytopenia (grade 3/4) (high certainty).
1 finding from 1 review
Intervention not reported
Alopecia (grade 2) · women with newly diagnosed EOC (stage Ic to IV)
The intervention leads to lower alopecia (grade 2) (high certainty).
1 finding from 1 review
Intervention not reported
Neuropathy (grade 3/4) · women with newly diagnosed EOC (stage Ic to IV)
The intervention leads to lower neuropathy (grade 3/4) (high certainty).
1 finding from 1 review